Contineum Therapeutics, Inc. (CTNM) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US21217B1008
Contineum Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -68.06 m USD |
| EBIT | -68.22 m USD |
| Net income | -59.98 m USD |
| Diluted EPS – continuing operations | -2.17 USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
More stocks
- Ranpak Holdings Corp. (PACK)
- Paz Corp (PAZ.SN)
- ISABELLA BANK CORP (ISBA)
- Information Services Group Inc. (III)
- Micro Contact Solution Co. Ltd (098120.KQ)
- Hangzhou Todaytec Digital Co Ltd Class A (300743.SZ)
- Te Chang Construction Co Ltd (5511.TWO)
- LNA Sante SA (LNA.PA)
- Weaver Fintech Ltd (WVR.JO)
- Hefei Jingsong Intelligent Technology Co. Ltd. A (688251.SS)
- Alto Ingredients, Inc. (ALTO)
- SES AI Corp (SES)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.